ABP-450 for Migraine Prevention

"Recruitment for this clinical trial has concluded. The initiation date was October 19th 2021 and the last update occurred on November 17th 2022. If you are searching for alternative studies, there are currently 172 trials that accept patients with migraine and 61 research projects where ABP-450 is being tested which are still accepting participants."

"There is some safety data available for ABP-450, so our team at Power assigned it a score of 2. This drug has yet to pass phase 3 trials, indicating the lack of efficacy results."

"ABP-450 is the leading treatment for urinary incontinence and can also prove beneficial in addressing spinal cord issues, botox injections, as well as overactive bladder syndrome."

"This experiment, conducted over a 48-week period from baseline to the end of treatment, will primarily measure the incidence of adverse events. Secondary outcomes include evaluating anti-drug antibodies for ABP-450 and assessing changes in monthly migraine days requiring medications as well as headache hours across treatment groups."

"To participate in this medical trial, prospective participants can find a recruiting centre such as Diex Recherche Québec in Quebec, META Medical Research Institute LLC located in Dayton or the New England Institute for Neurology and Headache situated in Stamford. Additionally, there are 48 other sites accepting enrolments now."

"Currently, there are 61 active clinical investigations into ABP-450 with 20 of them at the final Phase 3 stage. For the sake of convenience, most enrolment for these studies is occurring in Farmington Hills, Michigan; however, ABP-450 trials are taking place across 754 other sites around the world."

"The clinicaltrials.gov database reveals that this particular medical trial, which was first published on October 19th 2021, is not currently taking in new participants. However, 233 other studies are recruiting patients at the time of writing."